Talphera (TLPH) FCF Margin (2011 - 2025)

Talphera (TLPH) posted FCF Margin of 251000.0% for Q3 2025, down 1853.03% on a QoQ basis from 12851.85% in Q1 2025.

Analysis

Talphera (TLPH) FCF Margin (2011 - 2025) Analysis & Trends

Talphera has reported FCF Margin for 14 years, with the latest figure at 251000.0% in Q3 2025.

On a quarterly basis, FCF Margin changed N/A year-over-year to 251000.0% in Q3 2025; TTM through Jun 2026 was 1227000.0%, a 118400741.0% decrease from a year earlier, with the FY2025 full-year figure at 40585.71%, changed N/A from the prior year.
FCF Margin was 251000.0% for Q3 2025 at Talphera, down from 12851.85% in the prior quarter.
The five-year high for FCF Margin was 221.64% in Q3 2021, with the low at 401600.0% in Q4 2021.
Average FCF Margin over 4 years is 61724.89%, with a median of 2107.91% recorded in 2023.
The largest YoY upside for FCF Margin was 183565 bps in 2021 against a maximum downside of 40052168 bps in 2021.
Over 4 years, FCF Margin stood at 401600.0% in 2021, then jumped by 99 bps to 2041.4% in 2022, then surged by 31 bps to 1405.34% in 2023, then sank by 17760 bps to 251000.0% in 2025.
The last three FCF Margin figures came in at 251000.0% (Q3 2025), 12851.85% (Q1 2025), and 1405.34% (Q4 2023), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	34.70%
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	44.00%
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	30.39%
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	13.35%
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-388.28%
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	22.62%
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	14.91%
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-18,629.40%
10	Talphera	92.90 Mn	92.90 Mn	-	-

Historic Data

Download Data